helicide: structure given in first source [MeSH]
Helicid : no description available [CHeBI]
| ID Source | ID |
|---|---|
| PubMed CID | 12896796 |
| PubMed CID | 7573800 |
| CHEMBL ID | 201358 |
| CHEMBL ID | 461515 |
| SCHEMBL ID | 17822698 |
| SCHEMBL ID | 987981 |
| CHEBI ID | 189486 |
| MeSH ID | M0156615 |
| Synonym |
|---|
| helicide |
| F0542 |
| 4-(beta-d-allopyranosyloxy)benzaldehyde |
| 4-formylphenyl beta-d-allopyranoside |
| CHEMBL201358 , |
| 4-((2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)-tetrahydro-2h-pyran-2-yloxy)benzaldehyde |
| 4-((2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yloxy)benzaldehyde |
| bdbm50177404 |
| 4-[(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybenzaldehyde |
| CHEBI:189486 |
| A839856 |
| 4-(((2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)benzaldehyde |
| S3797 |
| AKOS025310966 |
| 4-(beta-d-allopyranosyloxy)-benzaldehyde |
| mfcd00210992 |
| benzaldehyde, 4-(b-d-allopyranosyloxy)- |
| SCHEMBL17822698 |
| 4-formylphenyl b-d-allopyranoside |
| hilicidum |
| helicid,(s) |
| 4-formylphenyl-o-b-d-allopyranoside |
| AS-30535 |
| HMS3885A06 |
| CS-0008901 |
| CCG-267289 |
| HY-N0343 |
| helicide; helicidum;4-formylphenyl--d-allopyranoside |
| 80154-34-3 |
| 4-((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)-tetrahydro-2h-pyran-2-yloxy)benzaldehyde |
| bdbm50245886 |
| 4-formylphenyl-o-beta-d-glucopyranoside |
| 4-formylphenyl-o-beta-dglucopyranoside |
| 4-((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yloxy)benzaldehyde |
| CHEMBL461515 , |
| 4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybenzaldehyde |
| helicin hydrate |
| 4'-formylphenyl-beta-d-glucopyranoside |
| 4-formylphenyl b-d-glucopyranoside |
| 4-(beta-d-glucopyranosyloxy)benzaldehyde |
| 26993-16-8 |
| AKOS015960450 |
| N88424 |
| SCHEMBL987981 |
| Q-201187 |
| W-202142 |
| 4-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)benzaldehyde |
| mfcd08704111 |
| AC-7974 |
| gastrodin impurity 1 |
| AS-49890 |
| A925039 |
| 4-formylphenyl-beta-d-glucopyranoside |
| 4-formylphenyl |a-d-glucopyranoside |
| CS-0139019 |
| PD182179 |
| (2s,3r,4s,5s,6r)-4-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-benzaldehyde |
| Class | Description |
|---|---|
| glycoside | A glycosyl compound resulting from the attachment of a glycosyl group to a non-acyl group RO-, RS-, RSe-, etc. The bond between the glycosyl group and the non-acyl group is called a glycosidic bond. By extension, the terms N-glycosides and C-glycosides are used as class names for glycosylamines and for compounds having a glycosyl group attached to a hydrocarbyl group respectively. These terms are misnomers and should not be used. The preferred terms are glycosylamines and C-glycosyl compounds, respectively. |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) |
|---|---|---|---|---|
| Acetylcholinesterase | Electrophorus electricus (electric eel) | IC50 | 0.4500 | AID383238 |
| Acetylcholinesterase | Electrophorus electricus (electric eel) | Ki | 0.7300 | AID383238 |
| Polyphenol oxidase 2 | Agaricus bisporus | IC50 | 1,473.3333 | AID411681; AID430880 |
| Succinate-semialdehyde dehydrogenase, mitochondrial | Homo sapiens (human) | IC50 | 1,000.0000 | AID260087 |
| 4-aminobutyrate aminotransferase, mitochondrial | Homo sapiens (human) | IC50 | 1,000.0000 | AID260086 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) |
|---|---|---|---|---|
| Farnesyl pyrophosphate synthase | Rattus norvegicus (Norway rat) | Kd | 328.0000 | AID1717384 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID260087 | Inhibitory activity against SSADH | 2006 | Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3 ISSN: 0960-894X | Inhibition of GABA shunt enzymes' activity by 4-hydroxybenzaldehyde derivatives. |
| AID444074 | Inhibition of mushroom tyrosinase at 200 uM | 2009 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 19, Issue:21 ISSN: 1464-3405 | Discovery of 4-functionalized phenyl-O-beta-D-glycosides as a new class of mushroom tyrosinase inhibitors. |
| AID383242 | Inhibition of horse serum BuChE upto 500 uM by Ellman's method | 2008 | European journal of medicinal chemistry, Jan, Volume: 43, Issue:1 ISSN: 0223-5234 | Synthesis and biological evaluation of helicid analogues as novel acetylcholinesterase inhibitors. |
| AID1442887 | Antiproliferative activity against human MCF7 cells by SRB assay | 2017 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8 ISSN: 1464-3405 | Bioactive drimane sesquiterpenoids and aromatic glycosides from Cinnamosma fragrans. |
| AID455418 | Inhibition of Torpedo california AChE at 1 mM by Ellman's method | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19 ISSN: 1464-3391 | Rational design and synthesis of highly potent anti-acetylcholinesterase activity huperzine A derivatives. |
| AID411681 | Inhibition of mushroom tyrosinase assessed as 3,4-dihydroxy-L-phenylalanine oxidation | 2008 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24 ISSN: 1464-3405 | Synthesis and biological evaluation of helicid analogues as mushroom tyrosinase inhibitors. |
| AID411682 | Inhibition of mushroom tyrosinase assessed as 3,4-dihydroxy-L-phenylalanine oxidation at 0.1 mM | 2008 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24 ISSN: 1464-3405 | Synthesis and biological evaluation of helicid analogues as mushroom tyrosinase inhibitors. |
| AID383241 | Inhibition of Electrophorus electricus AChE upto 500 uM by Ellman's method | 2008 | European journal of medicinal chemistry, Jan, Volume: 43, Issue:1 ISSN: 0223-5234 | Synthesis and biological evaluation of helicid analogues as novel acetylcholinesterase inhibitors. |
| AID260086 | Inhibitory activity against GABAT | 2006 | Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3 ISSN: 0960-894X | Inhibition of GABA shunt enzymes' activity by 4-hydroxybenzaldehyde derivatives. |
| AID411684 | Toxicity in mouse assessed by autopsy at 1200 mg/kg, po administered as single gavage dose after 20 days | 2008 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24 ISSN: 1464-3405 | Synthesis and biological evaluation of helicid analogues as mushroom tyrosinase inhibitors. |
| AID1717384 | Binding affinity to rat FPPS expressed in Escherichia coli BL21 (DE3) by isothermal titration calorimetry | 2020 | European journal of medicinal chemistry, Jan-15, Volume: 186ISSN: 1768-3254 | Structure-based virtual screening and biological evaluation of novel non-bisphosphonate farnesyl pyrophosphate synthase inhibitors. |
| AID1717383 | Inhibition of rat FPPS expressed in Escherichia coli BL21 (DE3) using GPP and IPP as substrate at 10 uM incubated for 10 mins by microplate reader | 2020 | European journal of medicinal chemistry, Jan-15, Volume: 186ISSN: 1768-3254 | Structure-based virtual screening and biological evaluation of novel non-bisphosphonate farnesyl pyrophosphate synthase inhibitors. |
| AID383238 | Inhibition of Electrophorus electricus AChE by Ellman's method | 2008 | European journal of medicinal chemistry, Jan, Volume: 43, Issue:1 ISSN: 0223-5234 | Synthesis and biological evaluation of helicid analogues as novel acetylcholinesterase inhibitors. |
| AID430880 | Inhibition of diphenolase activity of mushroom tyrosinase | 2009 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15 ISSN: 1464-3405 | Synthesis and evaluation of 5-benzylidene(thio)barbiturate-beta-D-glycosides as mushroom tyrosinase inhibitors. |
| AID411683 | Toxicity in mouse assessed as mortality at 1200 mg/kg, po administered as single gavage dose after 20 days | 2008 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24 ISSN: 1464-3405 | Synthesis and biological evaluation of helicid analogues as mushroom tyrosinase inhibitors. |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (7.41) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (37.04) | 29.6817 |
| 2010's | 10 (37.04) | 24.3611 |
| 2020's | 5 (18.52) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 30 (100.00%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4-hydroxybenzaldehyde | hydroxybenzaldehyde | EC 1.14.17.1 (dopamine beta-monooxygenase) inhibitor; mouse metabolite; plant metabolite | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| gallic acid | trihydroxybenzoic acid | antineoplastic agent; antioxidant; apoptosis inducer; astringent; cyclooxygenase 2 inhibitor; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; geroprotector; human xenobiotic metabolite; plant metabolite | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| corticosterone | 11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone | human metabolite; mouse metabolite | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| n-vinyl-2-pyrrolidinone | pyrrolidin-2-ones | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | ||
| propylparaben | benzoate ester; paraben; phenols | antifungal agent; antimicrobial agent | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| glycosides | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |||
| thiosemicarbazide | hydrazines; thiocarboxamide; thioureas | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sensitivity and Specificity | 0 | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Acute Liver Injury, Drug-Induced | 0 | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Allodynia | 0 | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Breast Cancer | 0 | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Breast Neoplasms | 0 | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Carbon Tetrachloride Poisoning | 0 | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Chemical and Drug Induced Liver Injury | 0 | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Chronic Insomnia | 0 | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Depression | 0 | 2019 | 2021 | 4.3 | medium | 0 | 0 | 0 | 0 | 2 | 1 | |
| Disease Models, Animal | 0 | 2017 | 2021 | 5.0 | medium | 0 | 0 | 0 | 0 | 2 | 1 | |
| Glial Cell Tumors | 0 | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Glioma | 0 | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Inflammation | 0 | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 2 | 0 | |
| Innate Inflammatory Response | 0 | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 2 | 0 | |
| Nerve Pain | 0 | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Neuralgia | 0 | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Sensitivity and Specificity | 0 | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 | |
| Sleep Initiation and Maintenance Disorders | 0 | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Article | Year |
|---|---|
| Bioavailability and pharmacokinetics profile of helicid in beagle dogs using gradient elution high performance liquid chromatography electrospray ionization mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, , Apr-15, Volume: 988 | 2015 |